DOCKET NO.: MOR-0277
Application No.: 10/813,502
Office Action Dated: May 30, 2006

PATENT
REPLY FILED UNDER EXPEDITED
PROCEDURE PURSUANT TO
37 CFR § 1.116

This listing of claims will replace all prior versions, and listings, of claims in the application.

Listing of Claims:

1-69. (Canceled)

70. (**Currently Amended**) A method for making a <u>genetically stable</u> cell that produces a therapeutically hypermutated immunogen comprising the steps of:

introducing into a cell that expresses a gene encoding a preselected immunogen *in vitro* a polynucleotide comprising a dominant negative allele of a mismatch repair gene, wherein said dominant negative allele is a truncation mutant of a PMS2,

selecting cells that comprise a mutation in said gene encoding said preselected immunogen; and

expressing a polynucleotide sequence of said mutated gene encoding said preselected immunogen in a genetically stable cell.

71. (Canceled)

72. (Previously Presented) The method of claim 70 wherein said introduction of said polynucleotide is in the presence of at least one DNA mutagen.

73. (Previously Presented) The method of claim 70 wherein the *PMS2* mismatch repair gene is human *PMS2*.

74. (Previously Presented) The method of claim 73 wherein the allele comprises a truncation mutation at codon 134.

75. (Previously Presented) The method of claim 74 wherein the truncation mutation is a thymidine at nucleotide 424 of wild-type PMS2.

76. (Previously Presented) The method of claim 70 wherein said step of selecting cells is based on a determination that the polynucleotide encoding said preselected immunogen

DOCKET NO.: MOR-0277
Application No.: 10/813,502
Office Action Dated: May 30, 2006

PATENT
REPLY FILED UNDER EXPEDITED
PROCEDURE PURSUANT TO
37 CFR § 1.116

comprises a mutation as compared to the polynucleotide of a parental cell prior to introduction of said dominant negative allele of a *PMS2* mismatch repair gene

77. (Previously Presented) A homogeneous culture of cells produced by the method of claim 70.